| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.
|
Infect Immun
|
2002
|
4.02
|
|
2
|
Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
|
Infect Immun
|
2005
|
3.72
|
|
3
|
Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria.
|
Infect Immun
|
2002
|
3.08
|
|
4
|
Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines.
|
Vaccine
|
2007
|
2.88
|
|
5
|
Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: effect of acquired immunity.
|
J Infect Dis
|
2013
|
2.47
|
|
6
|
Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria.
|
Vaccine
|
2005
|
2.21
|
|
7
|
The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody.
|
Nat Commun
|
2011
|
2.11
|
|
8
|
Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
|
Infect Immun
|
2006
|
2.02
|
|
9
|
Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.
|
Mol Ther
|
2011
|
1.92
|
|
10
|
Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
|
PLoS One
|
2008
|
1.81
|
|
11
|
Effective induction of high-titer antibodies by viral vector vaccines.
|
Nat Med
|
2008
|
1.76
|
|
12
|
ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.
|
Mol Ther
|
2012
|
1.76
|
|
13
|
Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex.
|
Proc Natl Acad Sci U S A
|
2006
|
1.74
|
|
14
|
The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites.
|
Infect Immun
|
2005
|
1.71
|
|
15
|
A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum.
|
Proc Natl Acad Sci U S A
|
2001
|
1.71
|
|
16
|
Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1.
|
Infect Immun
|
2003
|
1.65
|
|
17
|
Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians.
|
PLoS One
|
2007
|
1.60
|
|
18
|
Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria.
|
PLoS Clin Trials
|
2007
|
1.58
|
|
19
|
Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
|
PLoS One
|
2012
|
1.58
|
|
20
|
Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys.
|
J Infect Dis
|
2002
|
1.53
|
|
21
|
Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses.
|
PLoS One
|
2008
|
1.47
|
|
22
|
Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay.
|
Clin Vaccine Immunol
|
2009
|
1.46
|
|
23
|
Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens.
|
PLoS Pathog
|
2012
|
1.43
|
|
24
|
In vitro growth-inhibitory activity and malaria risk in a cohort study in mali.
|
Infect Immun
|
2009
|
1.39
|
|
25
|
Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination.
|
J Immunol
|
2008
|
1.34
|
|
26
|
Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide.
|
Vaccine
|
2006
|
1.33
|
|
27
|
Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum.
|
Infect Immun
|
2006
|
1.32
|
|
28
|
Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria.
|
J Infect Dis
|
2013
|
1.30
|
|
29
|
Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens.
|
Am J Trop Med Hyg
|
2006
|
1.30
|
|
30
|
Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.
|
Malar J
|
2007
|
1.29
|
|
31
|
Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates.
|
Vaccine
|
2007
|
1.28
|
|
32
|
Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.
|
PLoS One
|
2011
|
1.27
|
|
33
|
Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults.
|
PLoS One
|
2010
|
1.25
|
|
34
|
Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults.
|
PLoS One
|
2011
|
1.25
|
|
35
|
Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations.
|
Vaccine
|
2005
|
1.25
|
|
36
|
Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1.
|
PLoS One
|
2011
|
1.22
|
|
37
|
A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals.
|
Vaccine
|
2009
|
1.19
|
|
38
|
The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species.
|
Vaccine
|
2010
|
1.17
|
|
39
|
Evidence for erythrocyte-binding antigen 175 as a component of a ligand-blocking blood-stage malaria vaccine.
|
Proc Natl Acad Sci U S A
|
2011
|
1.17
|
|
40
|
Ex vivo cytokine and memory T cell responses to the 42-kDa fragment of Plasmodium falciparum merozoite surface protein-1 in vaccinated volunteers.
|
J Immunol
|
2008
|
1.15
|
|
41
|
High levels of antibodies to multiple domains and strains of VAR2CSA correlate with the absence of placental malaria in Cameroonian women living in an area of high Plasmodium falciparum transmission.
|
Infect Immun
|
2012
|
1.15
|
|
42
|
In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized.
|
Infect Immun
|
2007
|
1.15
|
|
43
|
Qualification of standard membrane-feeding assay with Plasmodium falciparum malaria and potential improvements for future assays.
|
PLoS One
|
2013
|
1.13
|
|
44
|
Formulation of vaccines containing CpG oligonucleotides and alum.
|
J Immunol Methods
|
2007
|
1.11
|
|
45
|
Discovery of GAMA, a Plasmodium falciparum merozoite micronemal protein, as a novel blood-stage vaccine candidate antigen.
|
Infect Immun
|
2011
|
1.11
|
|
46
|
The essential mosquito-stage P25 and P28 proteins from Plasmodium form tile-like triangular prisms.
|
Nat Struct Mol Biol
|
2005
|
1.06
|
|
47
|
Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1.
|
Infect Immun
|
2013
|
1.05
|
|
48
|
Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.
|
Vaccine
|
2010
|
1.02
|
|
49
|
Subdomain 3 of Plasmodium falciparum VAR2CSA DBL3x is identified as a minimal chondroitin sulfate A-binding region.
|
J Biol Chem
|
2010
|
1.01
|
|
50
|
Antibody-dependent transplacental transfer of malaria blood-stage antigen using a human ex vivo placental perfusion model.
|
PLoS One
|
2009
|
1.01
|
|
51
|
Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth.
|
Vaccine
|
2010
|
1.00
|
|
52
|
Characterization of a protective Escherichia coli-expressed Plasmodium falciparum merozoite surface protein 3 indicates a non-linear, multi-domain structure.
|
Mol Biochem Parasitol
|
2008
|
0.99
|
|
53
|
Humoral and cellular immunity to Plasmodium falciparum merozoite surface protein 1 and protection from infection with blood-stage parasites.
|
J Infect Dis
|
2013
|
0.99
|
|
54
|
Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay.
|
Infect Immun
|
2013
|
0.98
|
|
55
|
Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders.
|
Vaccine
|
2008
|
0.98
|
|
56
|
Improving malaria control in West Africa: interruption of transmission as a paradigm shift.
|
Acta Trop
|
2011
|
0.96
|
|
57
|
Multiple pathways for Plasmodium ookinete invasion of the mosquito midgut.
|
Proc Natl Acad Sci U S A
|
2014
|
0.96
|
|
58
|
Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen.
|
Vaccine
|
2007
|
0.95
|
|
59
|
Vaccination with conserved regions of erythrocyte-binding antigens induces neutralizing antibodies against multiple strains of Plasmodium falciparum.
|
PLoS One
|
2013
|
0.95
|
|
60
|
Plasmodium falciparum apical membrane antigen 1 vaccine elicits multifunctional CD4 cytokine-producing and memory T cells.
|
Vaccine
|
2009
|
0.94
|
|
61
|
Engineering the chloroplast targeted malarial vaccine antigens in Chlamydomonas starch granules.
|
PLoS One
|
2010
|
0.94
|
|
62
|
A multigene family that interacts with the amino terminus of plasmodium MSP-1 identified using the yeast two-hybrid system.
|
Eukaryot Cell
|
2002
|
0.94
|
|
63
|
Serologic imprint of dengue virus in urban Haiti: characterization of humoral immunity to dengue in infants and young children.
|
Am J Trop Med Hyg
|
2011
|
0.94
|
|
64
|
Strain-specific innate immune signaling pathways determine malaria parasitemia dynamics and host mortality.
|
Proc Natl Acad Sci U S A
|
2014
|
0.91
|
|
65
|
Sahel, savana, riverine and urban malaria in West Africa: Similar control policies with different outcomes.
|
Acta Trop
|
2011
|
0.91
|
|
66
|
Defibrotide interferes with several steps of the coagulation-inflammation cycle and exhibits therapeutic potential to treat severe malaria.
|
Arterioscler Thromb Vasc Biol
|
2011
|
0.91
|
|
67
|
Immunization of Aotus monkeys with recombinant cysteine-rich interdomain region 1 alpha protects against severe disease during Plasmodium falciparum reinfection.
|
J Infect Dis
|
2006
|
0.89
|
|
68
|
Allele specificity of gamma interferon responses to the carboxyl-terminal region of Plasmodium falciparum merozoite surface protein 1 by Kenyan adults with naturally acquired immunity to malaria.
|
Infect Immun
|
2010
|
0.89
|
|
69
|
Assessment of transmission-blocking activity of candidate Pvs25 vaccine using gametocytes from chimpanzees.
|
Am J Trop Med Hyg
|
2006
|
0.88
|
|
70
|
Plasma uric acid levels correlate with inflammation and disease severity in Malian children with Plasmodium falciparum malaria.
|
PLoS One
|
2012
|
0.88
|
|
71
|
T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein.
|
PLoS One
|
2012
|
0.86
|
|
72
|
Members of the merozoite surface protein 7 family with similar expression patterns differ in ability to protect against Plasmodium yoelii malaria.
|
Infect Immun
|
2004
|
0.84
|
|
73
|
Immunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein-1.
|
PLoS One
|
2012
|
0.83
|
|
74
|
A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies.
|
Infect Immun
|
2013
|
0.82
|
|
75
|
Relationship between malaria incidence and IgG levels to Plasmodium falciparum merozoite antigens in Malian children: impact of hemoglobins S and C.
|
PLoS One
|
2013
|
0.82
|
|
76
|
Non-apical membrane antigen 1 (AMA1) IgGs from Malian children interfere with functional activity of AMA1 IgGs as judged by growth inhibition assay.
|
PLoS One
|
2011
|
0.82
|
|
77
|
Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunized.
|
Vaccine
|
2011
|
0.82
|
|
78
|
Effects of age, hemoglobin type and parasite strain on IgG recognition of Plasmodium falciparum-infected erythrocytes in Malian children.
|
PLoS One
|
2013
|
0.82
|
|
79
|
Broadly reactive antibodies specific for Plasmodium falciparum MSP-1(19) are associated with the protection of naturally exposed children against infection.
|
Malar J
|
2012
|
0.81
|
|
80
|
Evaluation of the immunogenicity and vaccine potential of recombinant Plasmodium falciparum merozoite surface protein 8.
|
Infect Immun
|
2012
|
0.81
|
|
81
|
A potential role for plasma uric acid in the endothelial pathology of Plasmodium falciparum malaria.
|
PLoS One
|
2013
|
0.80
|
|
82
|
RALP1 is a rhoptry neck erythrocyte-binding protein of Plasmodium falciparum merozoites and a potential blood-stage vaccine candidate antigen.
|
Infect Immun
|
2013
|
0.80
|
|
83
|
Preparation, crystallization and preliminary X-ray analysis of a complex between the Plasmodium vivax sexual stage 25 kDa protein Pvs25 and a malaria transmission-blocking antibody Fab fragment.
|
Acta Crystallogr D Biol Crystallogr
|
2004
|
0.77
|
|
84
|
Effect of ingested human antibodies induced by RTS, S/AS01 malaria vaccination in children on Plasmodium falciparum oocyst formation and sporogony in mosquitoes.
|
Malar J
|
2014
|
0.76
|
|
85
|
Immunisation against a serine protease inhibitor reduces intensity of Plasmodium berghei infection in mosquitoes.
|
Int J Parasitol
|
2013
|
0.76
|